Please assess the completion status of the following clinical trial:

Trial Title: Metronomic Therapy in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Metastatic melanoma with measurable disease~* Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosoureas) and recovered from all ill~* Karnofsky Performance Status ≥60%~* Life expectancy ≥ twelve weeks~* Adequate end organ function~* Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study.~* Appropriate Contraception in both sexes~* The patient must be competent and signed informed consent.~EXCLUSION CRITERIA~* Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS.~* In patients with a prior history of invasive malignancy, less than five years in complete remission.~* Have evidence of significant co-morbid illness such as uncontrolled diabetes - Uncontrolled brain metastasis: Patients with brain metastasis most have been treated with brain radiation therapy or surgery and remain clinically stable for a minimum of 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined Low Dose Treatment (Type: EXPERIMENTAL): A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv

Based on this trial design, predict the completion outcome and termination type (if applicable).